PX1 Research provides certified, high-purity Ara-290 for laboratory evaluation in academic, medical, and industrial research settings. Every lot is manufactured in the USA, undergoes rigorous third-party analytical testing, and is supplied strictly for in vitro and preclinical research applications.
PX1 Research provides certified, high-purity Ara-290 for laboratory evaluation in academic, medical, and industrial research settings. Every lot is manufactured in the USA, undergoes rigorous third-party analytical testing, and is supplied strictly for in vitro and preclinical research applications.
When evaluating an Ara-290 supplier for laboratory experimentation, research institutions must prioritize verified peptide sequence integrity, analytical purity, and comprehensive lot control. PX1 Research supplies USA-manufactured Ara-290 peptide (also known as Cibinetide) synthesized to exceed 98% purity. Each lot is accompanied by a third-party Certificate of Analysis (COA) confirming chemical identity via mass spectrometry, purity via reverse-phase high-performance liquid chromatography, and low endotoxin thresholds.
Choosing a validated domestic supplier ensures that experimental assays measuring receptor binding, cell signaling, and tissue preservation remain reproducible and free from confounding contaminants such as residual trifluoroacetic acid (TFA), heavy metals, or bacterial endotoxins.
Ara-290 is an 11-amino acid linear peptide (sequence: Pyroglutamate-Glutamate-Proline-Threonine-Proline-Aspartate-Threonine-Tyrosine-Glutamine-Alanine-Lysine) derived from the helix B domain of erythropoietin (EPO). Unlike native EPO, Ara-290 was rationally engineered to selectively engage the innate repair receptor (IRR) without stimulating erythropoiesis or hematopoiesis.
In native biological systems, erythropoietin mediates red blood cell production by binding to the homodimeric EPO receptor (EPOR2). However, under tissue stress or inflammatory conditions, an alternative heteromeric complex forms—comprising two EPO receptor subunits and two common beta receptor (CD131) subunits. This complex, termed the innate repair receptor, initiates downstream tissue-protective and anti-inflammatory pathways upon ligand binding. Ara-290 selectively targets this heteromer, allowing investigators to isolate tissue repair signaling from hematopoietic activity in laboratory models.
Preclinical studies indicate that Ara-290 acts as a potent agonist of the heteromeric innate repair receptor (EPOR/CD131 heterodimer). Upon receptor engagement, Ara-290 triggers downstream signaling cascades that modulate nuclear factor kappa B (NF-κB) transcription, downregulate pro-inflammatory cytokines, and suppress apoptotic pathways in stressed parenchymal and neural tissues.
Key molecular mechanisms observed in laboratory models include:
1. Modulation of Inflammatory Signaling: In vitro assays demonstrate that IRR activation by Ara-290 inhibits the transcription of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) in macrophage and microglial cell cultures.
2. Anti-Apoptotic Effects: Cell culture models subjected to ischemia-reperfusion or oxidative stress show reduced caspase-3 activation and decreased apoptotic signaling following treatment with EPO-derived tissue-protective peptides.
3. Axonal and Neuronal Maintenance: In rodent nerve injury models, engagement of the innate repair receptor promotes neurite outgrowth and preserves small non-myelinated C-fibers and thinly myelinated A-delta fibers without inducing polycythemia or altering hematocrit levels.
The scientific literature surrounding Ara-290 focuses extensively on its role in metabolic, inflammatory, and neurodegenerative disease models. In animal models of peripheral small-fiber neuropathy, administration of Ara-290 has been documented to mitigate thermal hyperalgesia and mechanical allodynia while encouraging intraepidermal nerve fiber density (IENFD) regeneration.
Furthermore, in vitro data indicate that Ara-290 protects vascular endothelial cells from hyperglycemia-induced oxidative stress and apoptosis. Research groups utilizing mouse and rat models of diabetic kidney disease and inflammatory bowel disease report significant reductions in tissue fibrosis, inflammatory cell infiltration, and structural tissue degeneration. Scientists researching these pathways can explore related concepts in our comprehensive preclinical research library.
The reliability of preclinical experimental data depends entirely on the chemical quality and consistency of the reagents used. When selecting an Ara-290 supplier, procurement specialists should verify that the manufacturer fulfills several critical operational standards:
Third-Party Testing by ISO 17025 Accredited Laboratories: COAs should never be self-issued by the synthesizer. Independent laboratory verification ensures objective analytical data.
Lot-Specific Documentation: Every individual vial lot must have a dedicated COA displaying true, unedited chromatograms and mass spectra rather than generic template documents.
USA-Based Synthesis: Domestic manufacturing under Good Manufacturing Practice (GMP) compliant guidelines provides strict oversight of raw materials, peptide synthesis parameters, and purification steps.
Endotoxin Quantification: High levels of lipopolysaccharides (LPS) can stimulate innate immune responses in vitro and in vivo, falsifying research outcomes regarding inflammatory signaling.
At PX1 Research, every batch of Ara-290 undergoes rigorous multi-modal testing before release to the scientific community. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is utilized to determine overall chemical purity, resolving the target peptide from synthesis byproducts, truncated sequences, and target-adjacent impurities.
Liquid Chromatography-Mass Spectrometry (LC-MS) confirms the exact molecular weight and amino acid sequence identity, verifying the theoretical mass of Ara-290 (1257.34 Da). Additionally, chromogenic Limulus Amebocyte Lysate (LAL) assays are performed to ensure endotoxin levels remain strictly below <0.01 EU/mg, protecting cellular assays and animal models from bacterial endotoxin interference. Investigators looking to stock their laboratories with verified reagents can explore our full catalog of tissue-protective peptides.
In preclinical studies evaluating inflammation and tissue regeneration, researchers often compare Ara-290 against other specialized signaling peptides. While Ara-290 acts specifically on the EPOR/CD131 innate repair receptor to alter NF-κB transcription, compounds like BPC-157 target growth factor pathways, focal adhesion kinase, and nitric oxide synthesis to accelerate musculoskeletal repair.
Similarly, KPV peptide, a tripeptide fragment derived from alpha-melanocyte-stimulating hormone (α-MSH), operates primarily through cellular translocation to attenuate nuclear NF-κB activity in inflammatory intestinal models. Meanwhile, peptides like GHK-Cu modulate gene expression associated with extracellular matrix remodeling and collagen synthesis. Understanding these distinct mechanistic pathways allows researchers to select the precise peptide ligand required for their specific experimental model.
Ara-290 is supplied as a lyophilized (freeze-dried) powder to maximize chemical stability during transport and long-term storage. For optimal preservation, lyophilized vials should be stored at -20°C upon arrival, protected from light and moisture.
For reconstitution in laboratory settings, researchers typically utilize sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4), depending on the requirements of the downstream assay. The lyophilized cake should be brought to room temperature before reconstitution to prevent condensation inside the vial. Gentle swirling is recommended; vigorous vortexing should be avoided to prevent mechanical shear stress and peptide aggregation. Once reconstituted, liquid solutions should be aliquoted into single-use microcentrifuge tubes and stored at -80°C to minimize freeze-thaw degradation cycles.
PX1 Research serves as a trusted supplier for academic universities, contract research organizations (CROs), and biotechnology firms worldwide. We provide flexible fulfillment solutions, ranging from individual analytical vials to bulk custom manufacturing runs.
Principal investigators and procurement teams seeking reliable supply chains can establish a wholesale lab account to access volume tiering, dedicated account management, and standardized lot reservation for long-term longitudinal studies. All orders ship directly from our state-of-the-art dispatch facilities in California and Arizona, with same-day shipping available Monday through Friday for standard orders.
What is Ara-290 intended for in laboratory settings?
Ara-290 (Cibinetide) is intended strictly for in vitro laboratory assays and preclinical animal research evaluating innate repair receptor (IRR) signaling, inflammatory cascade modulation, and tissue preservation. It is not for human or veterinary use.
How does PX1 Research verify the purity of Ara-290?
Every lot of Ara-290 from PX1 Research is analyzed by independent ISO 17025 accredited laboratories using RP-HPLC for purity analysis (>98%), LC-MS for molecular mass verification, and LAL assays to ensure endotoxin levels remain below 0.01 EU/mg.
What is the molecular difference between Ara-290 and Erythropoietin (EPO)?
Ara-290 is an 11-amino acid peptide synthesized from the structural sequence of EPO's helix B domain. Unlike full-length EPO, Ara-290 selectively binds the heteromeric innate repair receptor (EPOR/CD131) and does not bind the homodimeric EPO receptor, meaning it does not stimulate red blood cell production.
Where does PX1 Research manufacture and ship its peptides?
PX1 Research products are manufactured in GMP-compliant facilities within the USA. Orders are fulfilled directly from our domestic warehouse hubs in California and Arizona, offering same-day dispatch for orders placed Monday through Friday.
How should lyophilized Ara-290 be stored upon receipt?
Lyophilized Ara-290 should be stored at -20°C or -80°C in a dry, dark environment. Under these conditions, the desiccated peptide maintains chemical stability for up to 24 months.
What solvents are suitable for reconstituting Ara-290 in research?
Common reconstitution media for preclinical work include sterile Bacteriostatic Water, sterile normal saline (0.9% NaCl), or sterile phosphate-buffered saline (PBS, pH 7.4). Solvents should be selected based on the specific requirements of the cellular or animal model.
Does PX1 Research provide lot-specific Certificates of Analysis?
Yes. Every shipment includes access to public, lot-specific COAs displaying HPLC chromatograms, mass spectra, and endotoxin test results from independent third-party testing laboratories.
Can institutions purchase Ara-290 in bulk or wholesale quantities?
Yes. Institutional buyers, academic laboratories, and biotech firms can apply for a wholesale lab account with PX1 Research to secure bulk pricing, custom synthesis options, and reserved single-lot batches for longitudinal trials.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.